FIELD: biotechnology.
SUBSTANCE: described is a combination of the obinutuzumab with a CD22 antibody-drug conjugate, which is anti-CD22-MC-vc-PAB-MMAE, for treating CD20 expressing cancer, wherein the anti-CD22 antibody in said conjugate contains a variable light chain domain of SEQ ID NO: 50 and heavy chain variable domain SEQ ID NO: 51.
EFFECT: invention extends the range of products for treating cancer, primarily a combination therapy for treating cancer types in which CD20 is expressed.
5 cl, 4 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY OF AFUCOSYLATED CD20 ANTIBODY WITH CD79b ANTIBODY-DRUGS CONJUGATE | 2014 |
|
RU2670971C9 |
| COMBINED THERAPY BASED ON CD20 ANTIBODY AND BTK INHIBITOR | 2014 |
|
RU2727650C2 |
| COMBINATION THERAPY BASED ON ANTI-CD20 ANTIBODY AND BTK INHIBITOR | 2021 |
|
RU2815679C2 |
| ANTIBODIES TO LAG3 | 2018 |
|
RU2778053C2 |
| COMBINED THERAPY BASED ON CD20 ANTIBODY COMBINED WITH BCL-2 INHIBITOR AND MDM2 INHIBITOR | 2016 |
|
RU2727196C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2718990C1 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2697098C1 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATION | 2007 |
|
RU2436796C9 |
| C5 ANTIBODIES AND METHODS FOR USING THEM | 2016 |
|
RU2742606C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
